BioSpace News Archive

Drug Development

OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLCA Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway

OncoC4, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ONC-392, as a single agent for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) who have had disease progression on prior anti-PD-(L)1 therapy.

April 26, 2022
·
4 min read
Business

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the appointment of Frank Karbe to its Board of Directors.

April 26, 2022
·
2 min read
Business

Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board

Sigyn Therapeutics, Inc. today announced the appointment of Donald J. Hillebrand,M.D. to its Scientific Advisory Board.

April 26, 2022
·
3 min read
Genetown

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 ConferencePresentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR)

Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that top-line data from the company’s pivotal Phase 3 ATTACK trial was presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference.

April 26, 2022
·
7 min read
Business

Optinose Announces Appointment of R. John Fletcher to the Board

Optinose today announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director.

April 26, 2022
·
2 min read
BioForest

Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership

Athira Pharma, Inc. announced that it has filed a new investor presentation with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Shareholders.

April 26, 2022
·
9 min read
Business

PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

PharmAbcine Inc. announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board.

April 26, 2022
·
4 min read
Genetown

NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING

Novaliq today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED), was presented as part of a podium symposium at the American Cataract and Refractive Surgery (ASCRS) annual meeting in Washington D.C. on April 24, 2022.

April 26, 2022
·
6 min read
WCG Selected as the Institutional Review Board of Record for The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative

PPMI is designed to identify biological markers and clinical changes associated with Parkinson’s disease risk, onset, and progression.

April 26, 2022
·
3 min read
Bio NC

Circassia Inc. Significantly Expands Reach of NIOX® FeNO Asthma Testing and Management Device With National Primary Care Distributor Agreements

Circassia Inc. announced today that it has successfully engaged with major primary care national sales partners to expand the distribution of NIOX VERO®, its FeNO testing device in the United States.

April 26, 2022
·
3 min read